ADx NeuroSciences develops proprietary state-of-the-art biomarker-assays diagnosing a wide variety of neurodegenerative diseases and conditions. The ADx tests provide unique access to early detection of Alzheimer's disease, Parkinson's disease, and traumatic brain injury.
ADx was founded in 2011 by 4 pioneers in biomarker development and Alzheimer’s disease research. We combine more than 45 years of knowledge and experience and presents an impressive track record developing superior, highly performant and unique diagnostic biomarkers. The ADx markers allow accurate diagnosis even before symptoms appear, provide valuable patient information and bridge the gap between disease and novel treatments.
Both in vitro diagnostic companies as well as pharma companies benefit from the ADx technology. IVD companies utilize the ADx biomarkers and antibodies on various automated platforms and test kits. In search of novel therapies, pharmaceutical companies rely on the ADx assays and services to accelerate and improve the design of large clinical trials.